Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter ended June 30, 2025.

Dr Reddy’s Laboratories on Wednesday said its consolidated net profit increased nearly 2 per cent year-on-year to Rs. 1,418 crore during the June quarter. Revenue increased 11.4 per cent to Rs. 8,545 crore for the period under review as against Rs 7,672.7 crore in the year-ago period.

The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew 5 per cent to Rs. 2,278 crore in the first quarter of June 2025 as compared to Rs. 2,160 crore in the same period a year ago. The margin was reported at 26.7 percent against 28.2 percent year-on-year (YoY).

Commenting on the results, Co-Chairman & MD, G V Prasad said: “We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market. We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development.”

Key Business Highlights for Q1 FY26

• Expanded partnership with Alvotech to co-develop, manufacture and co-commercialize pembrolizumab, a biosimilar candidate to Keytruda.

• Expanded collaboration with Sanofi to launch BeyfortusTM (Nirsevimab), a novel drug for preventing Respiratory Syncytial Virus (RSV) in India.

• Launched Sensimune in India, an immunotherapy product for house dust mite-induced allergies, in partnership with ALK-Abelló.